Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and Radiation After Gliadel Wafers in Newly Diagnosed GBM
NCT00238277Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2005
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide in glioblastoma multiforme (GBM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Feb 2005; status: terminated.
02
Drugs
temozolomide
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00238277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00238277.